{"denoms":[{"counts":[{"groupId":"BG000","value":"308"},{"groupId":"BG001","value":"104"},{"groupId":"BG002","value":"412"}],"units":"Participants"}],"groups":[{"description":"Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle\n\nNetupitant and Palonosetron\n\nDexamethasone","id":"BG000","title":"Netupitant and Palonosetron Plus Dexamethasone"},{"description":"Oral aprepitant hard capsule 125 mg (on Day 1) + 80 mg daily (for the following two days) and oral palonosetron soft capsule 0.50 mg (on Day 1) given with oral dexamethasone at each scheduled chemotherapy cycle.\n\nAprepitant\n\nPalonosetron\n\nDexamethasone","id":"BG001","title":"Aprepitant and Palonosetron Plus Dexamethasone"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.44","value":"56.5"},{"groupId":"BG001","spread":"11.70","value":"56.9"},{"groupId":"BG002","spread":"10.76","value":"56.6"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"51"},{"groupId":"BG002","value":"206"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"153"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"206"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"258"},{"groupId":"BG001","value":"87"},{"groupId":"BG002","value":"345"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"}]}],"title":"Black"},{"categories":[{"measurements":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"64"}]}],"title":"Asian"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"}],"populationDescription":"Safety Population, i.e. patients receiving study drugs (either netupitant/palonosetron combination or aprepitant/palonosetron regimen, both with dexamethasone)"}